ESTHER NEUMAN MUNICH GERMANYStock MarketsEuropean biotechs navigating a new financi...After the exuberance during the Covid-boost and the post-Covid hangover, 2024 was a rather calm year for the biotechnology sector. This provides an opportunity to take a step back and assess some emerging … more ➔
Sphene CapitalStock MarketsTrump’s win will affect the biotechn...During the conference calls on the latest quarterly reports, several recurring questions emerged: What consequences do you anticipate if Trump is to be re-elected? How will tariffs affect supply chains … more ➔
Curie.bioAntibodiesThe golden age of engineered therapeutic a...Therapeutic antibodies today represent a cornerstone of the treatment of various diseases including cancer, infectious, autoimmune, cardiovascular, haematological, metabolic, neurologic and ocular diseases, … more ➔
Analyst commentWhere has the conviction gone?2023 was another particularly tumultuous year for life sciences and, although the lingering effects of the last year are unlikely to change dramatically, the stabilisation of interest rates (off 16-year … more ➔
StatementThe future of health biotech innovation in... The 2023 State of the Union speech saw biotechnology rise as a priority for the European Union. It has been designated as a critical technology for Europe’s economic security. In March 2024, the European … more ➔
Clinical trialsSMEs suffer from CTISBorn with the aim of harmonising the application, evaluation, and supervision process of clinical trials conducted in EU countries, there is much room for improvement for the Clinical Trial Information … more ➔
Sphene CapitalAnalysisAre there bright times for biotech IPOs ah...Despite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive … more ➔
Cultivated FoodCultivated meat debate clouded by misinfor...As cultivated meat moves closer to commercialisation, we are seeing a worrying trend of misinformation entering the public debate. This food can play a vital role in ensuring Europe’s food system is … more ➔
IP commentIs "the hidden" publicly availab... The Enlarged Board of Appeal (EBoA) of the European Patent Office will decide upon a question of high relevance for patents in the field biotechnology. The question to be decided concerns the interpretation … more ➔
AnalysisEncouraging signs in a tough year for Euro...Continuing geopolitical uncertainty has perpetuated volatility in global markets, exacerbated by higher inflation and interest rates. The impact has left the biotech market in a limbo as investors eschew … more ➔
ESTHER NEUMAN MUNICH GERMANY
Sphene Capital
Curie.bio
